Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, noviembre 17
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
LB Pharmaceuticals Inc
LBRX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$42.99
-0.02
-0.05%
al cierre: Nov 16, 4:00 PM EST
$42.99
N/A
After hour: 4:00 PM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
LB Pharmaceuticals Financials
LB Pharmaceuticals (LBRX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
LB Pharmaceuticals On Track For Phase 3 NOVA-2 LB-102 Schizophrenia Topline Data In 1H27; Cash $403.8M Funds Operations Beyond Q2 2029
Benzinga Newsdesk
PRO
LB Pharmaceuticals Q3 GAAP EPS $(1.79) vs $(0.61) YoY
Benzinga Newsdesk
PRO
LB Pharmaceuticals Q2 EPS $(1.71) Misses $(0.80) Estimate
LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(1.71) per share which missed the analyst consensus estimate of $(0.80) by 113.75 percent. This is a 87.41 percent increase over losses of $(13.58) per
Benzinga Newsdesk
PRO
LB Pharmaceuticals Q1 EPS $(0.67) Beats $(0.75) Estimate
LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(0.67) per share which beat the analyst consensus estimate of $(0.75) by 10.67 percent. This is a 95.47 percent increase over losses of $(14.79) per share
Benzinga Newsdesk
PRO
LB Pharmaceuticals Q4 EPS $(0.45) Beats $(0.63) Estimate.
LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is a 96.81 percent increase over losses of $(14.12) per share
Benzinga Newsdesk
PRO
LB Pharmaceuticals Q3 EPS $(0.61) Beats $(0.63) Estimate
LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.63) by 3.17 percent. This is a 98.46 percent increase over losses of $(39.49) per share
Benzinga Newsdesk